QURE

uniQure N.V.

6.33 USD
+0.01 (+0.16%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

uniQure N.V. stock is up 8.58% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 10 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
20 Feb 16:24 17 Jan, 2025 7.00 PUT 124 10
20 Feb 16:24 17 Jan, 2025 7.00 CALL 118 53
20 Feb 16:24 17 Jan, 2025 7.00 CALL 118 53
20 Feb 16:24 17 Jan, 2025 7.00 CALL 118 53
20 Feb 16:24 17 Jan, 2025 7.00 PUT 118 10
20 Feb 16:24 17 Jan, 2025 7.00 PUT 118 10
20 Feb 16:24 17 Jan, 2025 7.00 CALL 118 53
20 Feb 16:24 17 Jan, 2025 7.00 CALL 124 53
20 Feb 16:24 17 Jan, 2025 7.00 PUT 118 10
22 Feb 15:22 19 Jul, 2024 7.00 CALL 400 251

About uniQure N.V.

uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.